Skip to main content
. 2022 Jun 27;12(6):1428–1437. doi: 10.1016/j.jceh.2022.06.008

Figure 1.

Figure 1

A. Body weight and B. liver weight showing no significant difference between the groups; telmisartan brings down total body weight and liver weight compared to other groups; C. Plasma ALT (mg/dL) and D. Liver fatty acid levels (mEq/g liver) were decreased in the telmisartan and N-163 groups compared to the other groups E. IL-6 mRNA expression levels were significantly decreased in AFO-202+N-163 and telmisartan groups.